Folic Acid-Doxorubicin-Double-Functionalized-Lipid-Core Nanocapsules: Synthesis, Chemical Structure Elucidation, and Cytotoxicity Evaluation on Ovarian (OVCAR-3) and Bladder (T24) Cancer Cell Lines
- PMID: 33608808
- DOI: 10.1007/s11095-021-02989-y
"V体育2025版" Folic Acid-Doxorubicin-Double-Functionalized-Lipid-Core Nanocapsules: Synthesis, Chemical Structure Elucidation, and Cytotoxicity Evaluation on Ovarian (OVCAR-3) and Bladder (T24) Cancer Cell Lines
Abstract
Purpose: Folic acid-doxorubicin-double-functionalized-lipid-core nanocapsules (LNC-CS-L-Zn+2-DOX-FA) were prepared, characterized, and evaluated in vitro against ovarian and bladder cancer cell lines (OVCAR-3 and T24). VSports手机版.
Methods: LNC-CS-L-Zn+2-DOX-FA was prepared by self-assembly and interfacial reactions, and characterized using liquid chromatography, particle sizing, transmission electron microscopy, and infrared spectroscopy. Cell viability and cellular uptake were studied using MTT assay and confocal microscopy V体育安卓版. .
Results: The presence of lecithin allows the formation of nanocapsules with a lower tendency of agglomeration, narrower size distributions, and smaller diameters due to an increase in hydrogen bonds at the surface. LNC-L-CS-Zn+2-DOX-FA, containing 98. 00 ± 2. 34 μg mL-1 of DOX and 105. 00 ± 2. 05 μg mL-1 of FA, had a mean diameter of 123 ± 4 nm and zeta potential of +12. 0 ± 1. 3 mV. After treatment with LNC-L-CS-Zn+2-DOX-FA (15 μmol L-1 of DOX), T24 cells had inhibition rates above 80% (24 h) and 90% (48 h), whereas OVCAR-3 cells showed inhibition rates of 68% (24 h) and 93% (48 h), showing higher cytotoxicity than DOX. HCl V体育ios版. The fluorescent-labeled formulation showed a higher capacity of internalization in OVCAR-3 compared to T24 cancer cells. .
Conclusion: Lecithin favored the increase of hydrogen bonds at the surface, leading to a lower tendency of agglomeration for nanocapsules VSports最新版本. LNC-CS-L-Zn+2-DOX-FA is a promising therapeutic agent against tumor-overexpressing folate receptors. .
Keywords: OVCAR-3: ovarian cancer line; T24: bladder cancer line; doxorubicin; folic acid; lipid-core nanocapsules. V体育平台登录.
References
-
- Saini R, Saini S, Sharma S. Nanotechnology: the future medicine. J Cutan Aesthet Surg. 2010;3(1):32–3. - VSports在线直播 - PubMed - PMC
-
- Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recente success in drug delivery. Clin Trans Med. 2010;6(1):1–21.
-
- Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I. The new era of nanotechnology, an alternative to change cancer treatment. Drug design Development and Therapy. 2017;11:2871–90.
-
- Dawidczyk CM, Russell LM, Searson PC. Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Frontiers in Chemistry. 2014;2(69):1–13.
-
- Abd Ellah NH, Abouelmagd SA. Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges. Expert Opinion on Drug Deliver. 2017;14(2):201–14.
MeSH terms
- "V体育官网入口" Actions
- "VSports" Actions
- Actions (V体育安卓版)
- Actions (V体育官网入口)
- V体育2025版 - Actions
- VSports注册入口 - Actions
Substances
- Actions (V体育官网)
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical